Retention in care during the first 3 years of antiretroviral therapy for women in Malawi's option B+ programme: an observational cohort study

Andreas D. Haas(Institute of Social and Preventive Medicine), Olivia Keiser(University of Geneva), Andreas Jahn(University of Washington), Frank Chimbwandira(Ministry of Health), Lyson Tenthani(Ministry of Health), Oliver Jintha Gadabu(Research for Equity And Community Health Trust), Kali Tal(EU Business School, Geneva), Malango Msukwa(University of Bern), Adrian Spoerri(Institute of Social and Preventive Medicine), Joep J. van Oosterhout(Dignitas International)
The Lancet HIV
March 9, 2016
10.1016/s2352-3018(16)00008-4
Cited by 177

Related Papers

Cancer Risk in the Swiss HIV Cohort Study: Associations With Immunodeficiency, Smoking, and Highly Active Antiretroviral Therapy
|JNCI Journal of the National Cancer Institute|2005|857
Retention in care under universal antiretroviral therapy for HIV-infected pregnant and breastfeeding women (‘Option B+’) in Malawi
|AIDS|2014|375
Changing patterns of cancer incidence in the early- and late-HAART periods: the Swiss HIV Cohort Study
|British Journal of Cancer|2010|301
Prevention of mother-to-child transmission of HIV and the health-related Millennium Development Goals: time for a public health approach
|The Lancet|2011|237
The Impact of the COVID-19 Pandemic and Associated Control Measures on the Mental Health of the General Population
|Annals of Internal Medicine|2022|189